CN107709328A - 咪唑衍生物及其中间体的制备方法和晶型 - Google Patents

咪唑衍生物及其中间体的制备方法和晶型 Download PDF

Info

Publication number
CN107709328A
CN107709328A CN201680031461.2A CN201680031461A CN107709328A CN 107709328 A CN107709328 A CN 107709328A CN 201680031461 A CN201680031461 A CN 201680031461A CN 107709328 A CN107709328 A CN 107709328A
Authority
CN
China
Prior art keywords
preparation
crystal form
liters
compound
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680031461.2A
Other languages
English (en)
Other versions
CN107709328B (zh
Inventor
石卫华
徐峰
王峥
李卫东
吴灵慧
李宏伟
曾明高
赖焜民
江志赶
贺海鹰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Shandong Danhong Pharmaceutical Co Ltd
Original Assignee
Shandong Danhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Danhong Pharmaceutical Co Ltd filed Critical Shandong Danhong Pharmaceutical Co Ltd
Publication of CN107709328A publication Critical patent/CN107709328A/zh
Application granted granted Critical
Publication of CN107709328B publication Critical patent/CN107709328B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B41/00—Formation or introduction of functional groups containing oxygen
    • C07B41/06—Formation or introduction of functional groups containing oxygen of carbonyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/04—Formation or introduction of functional groups containing nitrogen of amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Thermal Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明公开了一种咪唑衍生物的制备方法及其A晶型和B晶型，本发明还公开了式(Ⅰ)化合物及其中间体的制备方法。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201680031461.2A 2015-06-08 2016-06-07 咪唑衍生物及其中间体的制备方法和晶型 Active CN107709328B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015103091064 2015-06-08
CN201510309106 2015-06-08
PCT/CN2016/085104 WO2016197908A1 (zh) 2015-06-08 2016-06-07 咪唑衍生物及其中间体的制备方法和晶型

Publications (2)

Publication Number Publication Date
CN107709328A true CN107709328A (zh) 2018-02-16
CN107709328B CN107709328B (zh) 2021-03-05

Family

ID=57502897

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680031461.2A Active CN107709328B (zh) 2015-06-08 2016-06-07 咪唑衍生物及其中间体的制备方法和晶型

Country Status (9)

Country Link
US (3) US10227309B2 (zh)
EP (1) EP3305790B1 (zh)
JP (1) JP6548751B2 (zh)
CN (1) CN107709328B (zh)
ES (1) ES2821649T3 (zh)
HK (1) HK1244807A1 (zh)
PT (1) PT3305790T (zh)
TW (1) TWI695005B (zh)
WO (1) WO2016197908A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3305790B1 (en) 2015-06-08 2020-08-05 Shangdong Danhong Pharmaceutical Co., Ltd. Method for preparing imidazole derivative and intermediate thereof and crystal form
CN112057453B (zh) * 2019-08-26 2022-06-28 中检科医药科技(北京)集团有限公司 Enc002及其类似物在治疗或预防肠道病毒感染中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103347881A (zh) * 2010-12-16 2013-10-09 爱尔兰詹森研发公司 作为呼吸道合胞病毒抗病毒剂的氮杂苯并咪唑
WO2014060411A1 (en) * 2012-10-16 2014-04-24 Janssen R&D Ireland Rsv antiviral compounds
CN105793265B (zh) * 2013-12-10 2018-02-13 山东丹红制药有限公司 作为抗病毒剂的咪唑衍生物及其制药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4175289A (en) 1978-06-05 1979-11-20 International Business Machines Corporation Serrated Y-bar magnetic bubble switch
US4324794A (en) 1980-08-26 1982-04-13 Research Triangle Institute Inhibition of respiratory syncytial virus-induced cell fusion by amidino compounds
NO155805C (no) 1981-02-06 1987-06-10 Ucb Sa Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter.
US5256668A (en) 1993-03-17 1993-10-26 American Home Products Corporation Aminopyrimidine derivatives as antiviral agents for respiratory syncytial virus
BR9700939A (pt) 1996-02-13 1998-09-01 American Cyanamid Co Compostos aniônicos contendo traiazina úteis como agentes antivirais
CN1289248A (zh) 1998-01-29 2001-03-28 维洛药品公司 治疗或预防肺病毒感染及有关疾病的化合物、组合物和方法
CA2338147A1 (en) 1998-07-20 2000-02-03 Kuo-Long Yu Substituted benzimidazole antiviral agents
WO2010103306A1 (en) 2009-03-10 2010-09-16 Astrazeneca Uk Limited Benzimidazole derivatives and their use as antivaral agents
WO2012061590A1 (en) 2010-11-03 2012-05-10 Immunogen, Inc. Cytotoxic agents comprising new ansamitocin derivatives
GB201119538D0 (en) 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
CN103319599B (zh) 2013-05-27 2015-02-18 上海交联药物研发有限公司 一种抗人ErbB2抗体—美登木素偶联物及其应用
TWI671299B (zh) * 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為ｒｓｖ抗病毒化合物之螺脲化合物
GB201417707D0 (en) * 2014-10-07 2014-11-19 Viral Ltd Pharmaceutical compounds
EP3305790B1 (en) * 2015-06-08 2020-08-05 Shangdong Danhong Pharmaceutical Co., Ltd. Method for preparing imidazole derivative and intermediate thereof and crystal form

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103347881A (zh) * 2010-12-16 2013-10-09 爱尔兰詹森研发公司 作为呼吸道合胞病毒抗病毒剂的氮杂苯并咪唑
WO2014060411A1 (en) * 2012-10-16 2014-04-24 Janssen R&D Ireland Rsv antiviral compounds
CN105793265B (zh) * 2013-12-10 2018-02-13 山东丹红制药有限公司 作为抗病毒剂的咪唑衍生物及其制药用途

Also Published As

Publication number Publication date
CN107709328B (zh) 2021-03-05
US20200223802A1 (en) 2020-07-16
TW201704238A (zh) 2017-02-01
US20190218189A1 (en) 2019-07-18
US20180141915A1 (en) 2018-05-24
US10227309B2 (en) 2019-03-12
HK1244807A1 (zh) 2018-08-17
US10633347B2 (en) 2020-04-28
WO2016197908A1 (zh) 2016-12-15
PT3305790T (pt) 2020-10-19
EP3305790A4 (en) 2018-10-03
EP3305790A1 (en) 2018-04-11
ES2821649T3 (es) 2021-04-27
TWI695005B (zh) 2020-06-01
US10858322B2 (en) 2020-12-08
EP3305790B1 (en) 2020-08-05
JP2018517719A (ja) 2018-07-05
JP6548751B2 (ja) 2019-07-24

Similar Documents

Publication Publication Date Title
EP3097092B1 (en) Fused pyrimidines as inhibitors of p97 complex
EP2705032A1 (en) Dihydroquinoline derivatives as bromodomain inhibitors
KR20200051646A (ko) Ahr 억제제 및 이의 용도
MX2014015249A (es) Derivados de segunda generacion del antibiotico antifungico anfotericina b de n-sustiduidos y metodos de su preparacion y aplicacion.
ES2675580T3 (es) 1H-pirazol-5-olato sódico sustituido
WO2017101847A1 (zh) 吡啶并[1,2-a]嘧啶酮类似物、其晶型、其中间体及其制备方法
CA3040584A1 (en) Crystalline hydrate of the compound (2s,3r)-isopropyl 2-(((2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-1-((tetrahydro-2h-pyran-4-yl)methyl)-1h-benzo[d]imidazol-5-yl)methyl)amino)-3-hydroxybutanoate edisylate
US20200223802A1 (en) Process for preparing 1-isobutyryl-1'-((1-(4,4,4-trifluoro-butyl)-4,5,6,7- tetrahydro-1h-benzo[d]imidazol-2-yl)methyl)spiro[azetidine-3,3'-indolin]-2'-one
CN113278010A (zh) 一类蛋白激酶降解剂及其用途
TW201725204A (zh) 吡啶並｛１，２-ａ｝嘧啶酮類似物的晶型及其製備方法和中間體
CA2563959C (en) (1,10b-dihydro-2-(aminocarbonyl-phenyl)-5h-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as hiv viral replication inhibitors
SK2622001A3 (en) Tan-1057 derivatives
EP3896063B1 (en) Crystalline forms of the syk inhibitor 5-fluoro-1-methyl-3-[[5-[4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-(1h-pyrazol-3-yl)-2(1h)-quinolinone hydrochloride salt (1:1)
UA123709C2 (uk) КРИСТАЛІЧНІ ТА СОЛЬОВІ ФОРМИ 7Н-ПІРОЛО[2,3-d]ПІРИМІДИНІВ І СПОСІБ ЇХ ОДЕРЖАННЯ
US7384975B2 (en) Substituted furochromenes, preparation thereof and their antiinflammatory action
CN115536657A (zh) 一种联苯类衍生物抑制剂的盐、其晶型及其制备方法
EP0487930B1 (en) Benzo[C]phenanthridinium derivatives
CN108299430B (zh) 苯并二氮杂萘类生物碱及其合成方法与应用
AU2019297214B2 (en) Crystal forms of thiazole compound and application thereof
Hassan et al. Synthesis and antiviral evaluation of some new thieno [2, 3-d] pyrimidine S-glycosides
CN118026997A (zh) 以stat3为靶点的蛋白降解靶向嵌合体及其制备方法与医药用途
CN113646313A (zh) 一种a2a受体拮抗剂的盐型、晶型及其制备方法
Gupta et al. An efficient synthesis of novel 6, 12-dihydro (1) benzopyrano [3, 4-b][1, 4] benzothiazin-6-one
WO1986005784A1 (en) Antibiotics and preparation containing same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1244807

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant